Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01557335 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540

A Phase 1 study, sponsored by POZEN.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target

NCT01557335 is a Phase 1 study that has completed, run by POZEN. The registered enrollment target is 30 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01557335, a Phase 1 study, has completed, sponsored by POZEN.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target

Study Summary

This study is designed to provide data on platelet aggregation of PA32540 plus clopidogrel dosed separately compared to EC aspirin 81 mg plus EC omeprazole 40 mg plus clopidogrel dosed concomitantly.

Interventions

  • DRUG Plavix® and PA32540
  • DRUG EC aspirin (Bayer®) ,EC omeprazole (Prilosec®) , Clopidogrel (Plavix®)

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2010-11
Est. Completion 2011-02
Phase Phase 1

Sponsor

POZEN

24 total trials

What the Registry Record Tells You About NCT01557335

The ClinicalTrials.gov registry entry for NCT01557335 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is POZEN, which has 24 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Plavix® and PA32540 is the first listed.

NCT01557335 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01557335 about?

NCT01557335 is a clinical study titled "A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540". This study is designed to provide data on platelet aggregation of PA32540 plus clopidogrel dosed separately compared to EC aspirin 81 mg plus EC omeprazole 40 mg plus clopidogrel dosed concomitantly.

What is the current status of trial NCT01557335?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2010-11. Estimated completion is 2011-02.

What interventions are being tested in trial NCT01557335?

The interventions under investigation include: Plavix® and PA32540 (DRUG), EC aspirin (Bayer®) ,EC omeprazole (Prilosec®) , Clopidogrel (Plavix®) (DRUG).

Who is sponsoring clinical trial NCT01557335?

This trial is sponsored by POZEN, which has 24 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.